Market News & Trends
Aptose Prioritizes Development of First-in Class FLT3/BTK Inhibitor
Aptose Biosciences Inc. recently announced it will prioritize its resources toward the development of CG’806, an oral preclinical compound being developed for patients with FLT3-driven…
Mikron Automation Expands US Headquarters in Metro Denver
Mikron Automation and Denver-based Confluent Development are pleased to announce the expansion of Mikron Automation’s U.S. headquarters in Arapahoe County’s Dove Valley Business Park. The…
Terumo & Nemera Announce Validated Compatibility Between PLAJEX Polymer Prefillable Syringes & Safe'n'Sound
To serve the needs of the pharmaceutical industry and users, Nemera and Terumo agreed to cooperate to confirm compatibility between PLAJEXTM COP prefillable syringes and…
Mikron Automation Expands US Headquarters in Metro Denver
Mikron Automation and Denver-based Confluent Development are pleased to announce the expansion of Mikron Automation’s U.S. headquarters in Arapahoe County’s Dove Valley Business Park. The…
Dalton Pharma Services Announces Development & Manufacturing Agreement
Dalton Pharma Services recently announced the signing of a drug development and manufacturing services agreement with Cerium Pharmaceuticals, Inc., an emerging biopharmaceutical company based in…
Antibacterial Drugs Market Will Hit $35.6 Billion by 2022
The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth…
Antibacterial Drugs Market Will Hit $35.6 Billion by 2022
The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth…
Adamis Announces NDA Resubmission of its Epinephrine Pre-Filled Syringe Application
Adamis Pharmaceuticals Corporation recently announced the resubmission of the company’s New Drug Application (NDA) to the US FDA for its Epinephrine Pre-filled Syringe (PFS) product…
Symbiomix Submits New Drug Application to US FDA
Symbiomix recently announced submission of a new drug application (NDA) for Solosec (secnidazole oral granules) for the treatment of bacterial vaginosis (BV) to the US…
Tetraphase Pharmaceuticals Doses First Patient in Phase III Trial
Tetraphase Pharmaceuticals, Inc. recently announced dosing of the first patient in IGNITE3, the company’s Phase III clinical trial evaluating the efficacy and safety of once-daily…
Cycle Pharmaceuticals to Develop New Vascular Disease Treatment
Cambridge Enterprise has exclusively licensed intellectual property relating to the use of PARP inhibitor drugs for treating vascular disease to Cycle Pharmaceuticals. The University of…
Horizon Broadens Industry-Leading Gene Editing Capabilities
Horizon Discovery Group plc recently announced it has broadened its gene editing capabilities through the amendment of a pre-existing license with ERS Genomics to include…
Egalet Receives FDA Approval for Extended-Release Product Formulated With Abuse-Deterrent Properties
Egalet Corporation recently announced the US FDA has approved ARYMO ER (morphine sulfate) extended-release (ER) tablets C-II for the management of pain severe enough to…
University of Pittsburgh & Bayer Form Alliance to Advance Research for New Therapies
The University of Pittsburgh and Bayer have established a master collaboration agreement to advance research for heart, lung, and blood disease indications. This broad collaboration…
Pluristem’s Phase III Study Cleared by FDA
Pluristem Therapeutics Inc. recently announced that the company’s Phase III study of its PLX-PAD cells in the treatment of critical limb ischemia (CLI) was cleared…
MilliporeSigma Expands End-to-End Biodevelopment Centers
MilliporeSigma, a leading science and technology company, recently announced the expansion of its end-to-end biodevelopment centers to meet increasing customer demand for its turnkey portfolio…
G1 Therapeutics Initiates Three Drug Development Programs
G1 Therapeutics, Inc., a clinical-stage oncology company, recently announced the expansion of its pipeline of novel cancer therapies with the initiation of three development programs…
CytoDyn Files for Breakthrough Therapy Designation With the FDA
CytoDyn Inc. recently announced the company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection…
Elemental Impurities: Implications for Manufacturers of Drug Products, APIs & Excipients
By: Ulrich Reichert, PhD, Head of Pharma & Food Materials, Regulatory Management, Merck KGaA, Darmstadt, Germany Introduction The International Conference on Harmonization (ICH) finalized the…
Elemental Impurities: Implications for Manufacturers of Drug Products, APIs & Excipients
By: Ulrich Reichert, PhD, Head of Pharma & Food Materials, Regulatory Management, Merck KGaA, Darmstadt, Germany Introduction The International Conference on Harmonization (ICH) finalized the…
